重庆一医院为患儿注射疑似失效药 官方回应称存在违规将严肃处理 广告等商务合作，请点击这里 中新网重庆12月13日电 (梁钦卿)记者12月13日从重庆市卫生健康委员会获悉，关于网上反映的重庆医科 大学附属儿童医院为患儿注射疑似失效药的情况，经重庆市卫生健康委组建专项调查组初步核查，当事 医生确实存在违规存储药物情况，将依法依规对其进行严肃处理。 本文为转载内容，授权事宜请联系原著作权人 经初步核查，患儿马某某因确诊"脊髓性肌萎缩症(Ⅱ型)"于2025年12月9日收入重庆医科大学附属儿童 医院神经内科病房，进行诺西那生钠鞘内注射。当日医生取药后，于13时54分将拟注射治疗药物放入冰 箱冷冻层，14时17分将药物从冷冻层取出放入冷藏层，14时24分将药物从冷藏层取出复温，腰椎穿刺成 功后于14时34分开始鞘内注射药物，注射完药物后，同时观察患儿未见不良反应，于12月10日出院。出 院后，患方反映治疗药物诺西那生钠说明书记载该药物应在2℃至8℃下冷藏保存，不得冷冻，认为注射 药疑似失效。 中新经纬版权所有，未经书面授权，任何单位及个人不得转载、摘编或以其它方式使用。 关注中新经纬微信公众号(微信搜索"中新经纬"或"j ...

Core Viewpoint - The Chongqing Municipal Health Commission has initiated an investigation into the Chongqing Medical University Affiliated Children's Hospital regarding allegations of administering potentially ineffective medication to a patient with spinal muscular atrophy [1] Group 1: Investigation and Findings - A special investigation team was formed to verify the claims about the hospital's practices [1] - Initial findings revealed that the medication, Nusinersen, was improperly stored, as it should have been kept between 2°C and 8°C and not frozen [1] - The involved physician will face serious consequences for the violation of medication storage protocols [1] Group 2: Patient Care and Response - The patient, diagnosed with spinal muscular atrophy type II, was admitted on December 9, 2025, and discharged the following day without adverse reactions noted during the treatment [1] - The health commission is prioritizing the protection of patient health and is organizing expert consultations to assess the impact of the improper medication storage on the patient's condition [1] - A revised treatment plan will be developed to ensure the patient receives appropriate care [1] Group 3: Future Actions - The Chongqing Municipal Health Commission will continue to investigate the situation thoroughly and enhance medical quality and safety supervision [1] - There will be a focus on standardizing medical personnel's diagnostic and treatment behaviors to prevent future violations in medical services [1]

据重庆市卫生健康委专项调查组12日通报，针对网上反映的重庆医科大学附属儿童医院为患儿注射疑似失效药 的情况，经初步调查，当事医生存在违规存储药物情况，将依法依规严肃处理。 百万用户都在看 杀疯了！半小时500亿元！刚刚，重磅利好彻底引爆！ A股突发！芯片大牛股，终止重组！ 房地产，突传重磅！ AI，突传重磅！特朗普，正式签署！ 黑天鹅突袭！"AI交易"，全线重挫！ 违法和不良信息举报电话：0755-83514034 邮箱：bwb@stcn.com 券中社 × 券商中国 券 中 社 扫码下载券中社APP 扫码关注券商中国公众号 quanshangcn qzs.stcn.com 舞中 券中社APP 券 商 中 国 是 证 券 市 场 权 威 媒 体 《 证 券 时 报 》 旗 下 新 媒 体 , 券 商 中 国 对 该 平 台 所 刊 载 的 原 创 内 容 享 有 著 作 权 , 未 经 授 权 禁 止 转 载 ， 否 则 将 追 究 相 应 法 律 责 任 。 经初步核查，患儿马某某因确诊"脊髓性肌萎缩症（Ⅱ型）"于2025年12月9日收入重庆医科大学附属儿童医院 神经内科病房，进行诺西那生钠鞘内注射。当日医 ...

据王女士介绍，不同于普通注射，该药剂需先抽取患儿5毫升脑脊髓液与注射剂相兑，随后从腰部进行鞘注，"小孩很遭罪的。"孩子目前正处在治理窗口 期，共需接受4次鞘注，每支注射剂费用为3万3千多元，如果按照正常疗程进行注射，孩子能有机会独立行走，现在因第3针疑似失效注入，可能会影响后 续治疗进展。事发后，王女士从监控中看到，医务人员将注射剂从冰箱冷冻层拿出，随后用冷水冲洗、手搓等方式使药物快速化冻，"没有人及时来制止 这个行为，让我非常寒心。"目前，王女士已申请封存相关病历，等待后续处理。 重庆医科大学附属儿童医院工作人员回应荔枝新闻，相关部门正在与家属对接处理。重庆市卫健委回应称，已接到该事件投诉，正在协调处理中。 每经编辑｜段炼 12月13日，据重庆市卫生健康委消息，针对网上反映的重庆医科大学附属儿童医院为患儿注射疑似失效药的情况，经重庆市卫生健康委专项调查组初步调 查，当事医生存在违规存储药物情况，将依法依规严肃处理。 经初步核查，患儿马某某因确诊"脊髓性肌萎缩症（Ⅱ型）"于2025年12月9日收入重庆医科大学附属儿童医院神经内科病房，进行诺西那生钠鞘内注射。 当日医生取药后，于13时54分将拟注射治疗药物放入 ...

下一步，我委将继续深入调查核实相关情况，持续深入开展医疗质量安全监管，规范医务人员诊疗行 为，严防医疗服务中违规操作行为发生。感谢社会各界对医疗工作的关心关注。 八国发表联合声明 经初步核查，患儿马某某因确诊"脊髓性肌萎缩症(Ⅱ型)"于2025年12月9日收入重庆医科大学附属儿童 医院神经内科病房，进行诺西那生钠鞘内注射。当日医生取药后，于13:54将拟注射治疗药物放入冰箱 冷冻层，14:17将药物从冷冻层取出放入冷藏层，14:24将药物从冷藏层取出复温，腰椎穿刺成功后于 14:34开始鞘内注射药物，注射完药物后，同时观察患儿未见不良反应，于12月10日出院。出院后，患 方反映治疗药物诺西那生钠说明书记载该药物应在2℃—8℃下冷藏保存，不得冷冻，认为注射药疑似失 效。 经初步调查，当事医生确实存在违规存储药物情况，我委将依法依规对其进行严肃处理，始终以保护患 儿健康和积极救治为首要原则，迅速组织相关专业专家，会诊评估对患儿病情的影响，进一步制定治疗 方案，及时给予患儿专业规范救治。 重庆市卫生健康委专项调查组12月12日发布情况通报： 关于网上反映的重庆医科大学附属儿童医院为患儿注射疑似失效药的情况，我委高度 ...

新京报讯12月12日，重庆市卫生健康委专项调查组发布情况通报： 下一步，我委将继续深入调查核实相关情况，持续深入开展医疗质量安全监管，规范医务人员诊疗行 为，严防医疗服务中违规操作行为发生。 关于网上反映的重庆医科大学附属儿童医院为患儿注射疑似失效药的情况，我委高度重视，立即组建专 项调查组进入医院进行认真核查。经初步核查，患儿马某某因确诊"脊髓性肌萎缩症(Ⅱ型)"于2025年12 月9日收入重庆医科大学附属儿童医院神经内科病房，进行诺西那生钠鞘内注射。当日医生取药后，于 13:54将拟注射治疗药物放入冰箱冷冻层，14:17将药物从冷冻层取出放入冷藏层，14:24将药物从冷藏层 取出复温，腰椎穿刺成功后于14:34开始鞘内注射药物，注射完药物后，同时观察患儿未见不良反应， 于12月10日出院。出院后，患方反映治疗药物诺西那生钠说明书记载该药物应在2℃—8℃下冷藏保存， 不得冷冻，认为注射药疑似失效。经初步调查，当事医生确实存在违规存储药物情况，我委将依法依规 对其进行严肃处理，始终以保护患儿健康和积极救治为首要原则，迅速组织相关专业专家，会诊评估对 患儿病情的影响，进一步制定治疗方案，及时给予患儿专业规范救治 ...

Core Viewpoint - The Chongqing Municipal Health Commission has initiated an investigation into the improper storage of medication at the Chongqing Medical University Affiliated Children's Hospital, which may have led to the administration of ineffective drugs to a patient with spinal muscular atrophy [1][2] Group 1: Incident Details - A patient diagnosed with spinal muscular atrophy type II was admitted to the hospital on December 9, 2025, for intrathecal injection of Nusinersen [1] - The medication was improperly stored in a freezer before being moved to a refrigerator, contrary to the storage instructions that require it to be kept between 2°C and 8°C [1] - After the injection, the patient showed no adverse reactions and was discharged on December 10 [1] Group 2: Regulatory Response - The Chongqing Municipal Health Commission will take strict legal action against the involved physician for the violation of medication storage protocols [1] - The commission emphasizes the protection of patient health and will organize expert consultations to assess the impact on the patient's condition and develop a new treatment plan [1][2] - Ongoing investigations will focus on ensuring medical quality and safety, as well as regulating medical personnel's practices to prevent future violations [2]

Group 1 - The core viewpoint is that by 2026, the focus in the innovative drug market will shift from "BD supremacy" to "data supremacy," emphasizing the importance of clinical data and commercial capabilities in realizing revenue growth [1] - The pharmaceutical industry is expected to experience a reversal in 2025, led by innovative drugs, with significant benefits extending to the CXO and upstream supply chain, as well as notable gains in secondary sectors [2] - The Hong Kong stock market has seen remarkable performance in innovative drugs, with a peak increase of over 80% year-to-date, making it one of the most关注板块 in the first half of the year [2] Group 2 - The core catalysts for innovative drugs include policy support and the realization of BD opportunities, with significant transactions such as those by 3SBio and Innovent Biologics, which have seen upfront payments exceeding $1 billion [2] - A significant reform in the payment sector is underway, with the introduction of a dual-track system for medical insurance, aimed at addressing the gap in coverage for high-value innovative drugs [2] - By November 13, 2025, the number of license-out transactions by Chinese pharmaceutical companies has rapidly increased, with total upfront payments reaching $6.298 billion, a 53% year-on-year increase, and total transaction amounts reaching $118.862 billion, a 125% year-on-year growth [3]

Core Viewpoint - The company reported strong financial performance for the first half of 2025, with revenue and net profit showing significant year-on-year growth, indicating a robust business trajectory and potential for future expansion [1][2]. Financial Performance - In H1 2025, the company achieved revenue of 822 million yuan, representing a year-on-year increase of 12.50% [1][2]. - The net profit attributable to shareholders was 235 million yuan, up 24.55% year-on-year, while the net profit excluding non-recurring items reached 226 million yuan, reflecting a growth of 20.94% [1][2]. - The gross margin and net margin for H1 2025 were 60.11% and 28.58%, respectively, showing improvements of 309 basis points and 277 basis points compared to the previous year [2]. Business Segments - The raw material pharmaceutical business exhibited rapid growth, with revenue in H1 2025 reaching 700 million yuan, a year-on-year increase of 24.68% [3]. - Key product categories such as cardiovascular, respiratory, women's health, nervous system, and anti-infection raw materials showed steady growth, while new products in the peptide and oligonucleotide segments contributed to sales growth [3]. Future Outlook - The company anticipates continued growth in key products like Dydrogesterone, Abiraterone, and others, alongside new product launches expected to drive revenue increases over the next 3-5 years [2][4]. - The company is focusing on expanding hospital coverage for Dydrogesterone, with 1,754 new hospital additions in H1 2025, leading to a sales revenue of approximately 95.7 million yuan, a 3.5% increase year-on-year [2]. Investment Recommendations - The company is expected to maintain high growth rates in the coming years due to the ongoing expansion of existing products and the commercialization of potential blockbuster products [4]. - Revenue forecasts for 2025-2027 have been adjusted to 1.777 billion, 2.154 billion, and 2.591 billion yuan, respectively, with corresponding EPS estimates revised to 1.15, 1.47, and 1.84 yuan [4].

Core Insights - The National Healthcare Security Administration (NHSA) has released the initial review list for the "Commercial Insurance Innovative Drug Directory," marking a significant step in integrating commercial insurance with the national medical insurance system [2][3] - The list includes various high-value innovative drugs, such as CAR-T therapies and rare disease medications, which are expected to enhance market confidence and improve patient outcomes [2][6] Group 1: Commercial Insurance Directory - A total of 141 applications were received for the commercial insurance innovative drug directory, with 121 drug names passing the initial review [3] - The directory features expensive high-value innovative drugs, including CAR-T therapies, which have an average price in the million yuan range [3][4] - Some CAR-T products are being submitted for both basic medical insurance and commercial insurance, providing a second chance for reimbursement if they fail in the first round [4][5] Group 2: Rare Disease Medications - The commercial insurance directory includes 51 products for 52 rare diseases, potentially allowing patients to access previously unaffordable "orphan drugs" through commercial insurance [6] - The example of nusinersen for spinal muscular atrophy (SMA) illustrates the significant cost reduction from nearly 700,000 yuan to approximately 33,000 yuan after entering the insurance system [6] - The number of rare disease drugs in China is expected to increase, with 210 drug development pipelines projected for 2024, 38% of which are in Phase III clinical trials [6][7] Group 3: Market Dynamics and Future Outlook - The integration of commercial insurance with the national medical insurance system is seen as a flexible approach to facilitate access to high-value innovative drugs [7] - The expected results from national negotiations on drug pricing will be announced between October and November 2025, while the commercial insurance directory is set to be finalized by the end of September [7] - The evolving landscape indicates a narrowing gap between the availability and affordability of innovative treatments for patients [7]